12:00 AM
 | 
Sep 08, 2008
 |  BC Week In Review  |  Clinical News  |  Regulatory

Arenegyr regulatory update

FDA granted Orphan Drug designation for MolMed's Arenegyr to treat malignant pleural mesothelioma (MPM). The recombinant fusion...

Read the full 63 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >